Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
about
Immune therapy in type 1 diabetes mellitusLong-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in miceTAP1 I333V gene polymorphism and type 1 diabetes mellitus: a meta-analysis of 2248 cases.High-throughput sequencing of islet-infiltrating memory CD4+ T cells reveals a similar pattern of TCR Vβ usage in prediabetic and diabetic NOD miceClinical potential of antigen-specific therapies in type 1 diabetes.Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant.Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.Trials in type 1 diabetes: Antigen-specific therapies.Alteration of regulatory T cells in type 1 diabetes mellitus: a comprehensive review.Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges.Biomarkers for antigen immunotherapy in allergy and type 1 diabetes.Therapies to Preserve β-Cell Function in Type 1 Diabetes.Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD65-induced immune response.GAD65: a prospective vaccine for treating Type 1 diabetes?Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
P2860
Q28282846-A5CD12BD-F442-4092-A592-ADA6811EA073Q30370790-71A9461D-2275-4F4F-AB49-288EBF3D5D99Q33991679-B50825F4-6BF2-4BE4-B45E-D4A52BA35EEFQ35022826-6FABD828-B30F-4309-A251-D3863446C652Q37088212-0A9E9096-6D4D-4919-973B-3B9F2D056A62Q37130834-E87829B1-C610-410C-9D63-13924428610AQ37278210-79BE7E9D-02A9-4043-AD31-440B03521800Q38089387-74676D4D-73C4-4BA7-978A-E7E2D5E0FADFQ38236300-E6F0391C-63FF-48AD-A20C-A16A432F0F82Q38346930-E7CFF1D3-8CDC-47FF-9DA6-4806B1602B1DQ38539950-E99CD833-EB32-43EB-9060-DADBF8E2713DQ38662048-332C7A6B-A14C-4021-BDA0-E99043EFE035Q38867876-C235D64C-5F65-4125-A7CE-CC1FEA9F879AQ39290175-91B6DA57-6E4F-4949-B152-9C7FE1B43B0DQ44417657-64CFCA13-136B-43A3-AD12-F038DE0C6EC8Q50954502-0F3BD9CA-7BD7-45BA-8BD7-310DFB93626AQ51330517-D04D8229-90F5-4B54-9D55-33E259C048F6Q55658907-5FA4842D-F8EA-4310-B2B8-0B9126210A1E
P2860
Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Long-lasting immune responses ...... children with type 1 diabetes.
@ast
Long-lasting immune responses ...... children with type 1 diabetes.
@en
Long-lasting immune responses ...... children with type 1 diabetes.
@nl
type
label
Long-lasting immune responses ...... children with type 1 diabetes.
@ast
Long-lasting immune responses ...... children with type 1 diabetes.
@en
Long-lasting immune responses ...... children with type 1 diabetes.
@nl
prefLabel
Long-lasting immune responses ...... children with type 1 diabetes.
@ast
Long-lasting immune responses ...... children with type 1 diabetes.
@en
Long-lasting immune responses ...... children with type 1 diabetes.
@nl
P2093
P2860
P50
P1433
P1476
Long-lasting immune responses ...... children with type 1 diabetes.
@en
P2093
Linda Akerman
Maria Hjorth
Mikael Chéramy
Mikael Pihl
Rosaura Casas
Stina Axelsson
P2860
P304
P356
10.1371/JOURNAL.PONE.0029008
P407
P577
2011-12-12T00:00:00Z